Conformis, Inc , a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation.
infoConformis is a micro cap stock with a total market cap of 17.80M.
infoThey trade on the NASDAQ and had their IPO 8 years and 1 month ago.
infoConformis currently employs 295 people.
infoAs of Wednesday, Aug 23 2023, Conformis’s share price is $2.26.
News Relating to Conformis
Market Watch
Conformis stock nearly doubles in active trading after cash buyout deal with Restor3d
Friday Jun 23 2023 at 06:50
Shares of Conformis Inc. CFMS, -2.11% rocketed 90.5% to pace all premarket gainers in active trading Friday, after the orthopedic patient care company announced an agreement to be acquired by Restor3d for a 96% premium. Trading volume swelled to more than 671,000 shares, compared with the full-day average of about 52,800 shares.
Zacks Investment Research
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
Monday May 08 2023 at 10:40
ConforMIS (CFMS) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.56. This compares to loss of $2.25 per share a year ago.
Seeking Alpha
Conformis, Inc. (CFMS) Q1 2023 Earnings Call Transcript
Monday May 08 2023 at 10:15
Conformis, Inc. (NASDAQ:CFMS ) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ET Company Participants Mark Augusti – President and CEO Bob Howe – CFO and Treasurer Conference Call Participants Eric Anderson – TD Cowen Steve Lichtman – Oppenheimer Joshua Jennings – TD Cowen Operator Good morning, and welcome to the First Quarter 2023 Earnings Conference Call for Conformis, Incorporated. My name is Tanya, and I will be your conference operator today.
GlobeNewsWire
Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023
Thursday Apr 13 2023 at 16:30
BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023.
Zacks Investment Research
ConforMIS (CFMS) Moves to Buy: Rationale Behind the Upgrade
Monday Mar 06 2023 at 13:33
ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Seeking Alpha
Conformis, Inc. (CFMS) Q4 2022 Earnings Call Transcript
Wednesday Mar 01 2023 at 21:49
Conformis, Inc. (NASDAQ:CFMS ) Q4 2022 Results Conference Call March 1, 2023 4:30 PM ET Company Participants Mark Augusti – President and Chief Executive Officer Bob Howe – CFO and Treasurer Conference Call Participants Steven Lichtman – Oppenheimer Eric Anderson – Cowen Operator Good afternoon, and welcome to the Fourth Quarter and Full Year 2022 Earnings Conference Call for Conformis, Inc. My name is Josh, and I will be your conference operator today. All lines have been placed on listen-only mode to prevent any background noise.
GlobeNewsWire
Conformis, Inc. to Participate in Upcoming Investor Conferences
Tuesday Feb 21 2023 at 16:15
BILLERICA, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate at two upcoming investor conferences.
GlobeNewsWire
Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022
Monday Jan 23 2023 at 16:30
BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023.
Seeking Alpha
Conformis, Inc. (CFMS) Q3 2022 Earnings Call Transcript
Wednesday Nov 02 2022 at 21:59
Conformis, Inc. (NASDAQ:CFMS ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Augusti – President and CEO Bob Howe – CFO and Treasurer Conference Call Participants Eric Anderson – Cowen Caitlin Cronin – Canaccord Genuity Operator Good morning and welcome to the Third Quarter 2022 Earnings Conference Call for Conformis, Inc. My name is Shannon, and I will be your conference operator today. All lines have been placed on listen-only mode to prevent any background noise.
Zacks Investment Research
ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates
Wednesday Nov 02 2022 at 21:04
ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022
Wednesday Oct 05 2022 at 16:30
BILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Wednesday, November 2, 2022.
GlobeNewsWire
Conformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference
Monday Aug 29 2022 at 16:30
BILLERICA, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
Seeking Alpha
Conformis, Inc. (CFMS) CEO Mark Augusti on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 09 2022 at 11:55
Start Time: 08:30 January 1, 0000 8:57 AM ET Conformis, Inc. (NASDAQ:CFMS ) Q2 2022 Earnings Conference Call August 09, 2022, 08:30 AM ET Company Participants Mark Augusti – President and CEO Bob Howe – CFO and Treasurer Conference Call Participants Eric Anderson – Cowen Steven Lichtman – Oppenheimer Caitlin Cronin – Canaccord Genuity Operator Good morning, and welcome to the Second Quarter 2022 Earnings Conference Call for Conformis, Inc. My name is Justin, and I will be your conference operator today. All lines have been placed on mute to prevent any background noise.
Zacks Investment Research
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
Monday Aug 08 2022 at 19:34
ConforMIS (CFMS) delivered earnings and revenue surprises of -12.50% and 1.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
Tuesday Jul 05 2022 at 16:30
BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022.
GlobeNewsWire
Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference
Tuesday May 10 2022 at 08:00
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright (HCW) Global Investment Conference.
Seeking Alpha
Conformis, Inc. (CFMS) CEO Mark Augusti on Q1 2022 Results – Earnings Call Transcript
Wednesday May 04 2022 at 15:04
Conformis, Inc. (NASDAQ:CFMS ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Mark Augusti – President and Chief Executive Officer Bob Howe – Chief Financial Officer Conference Call Participants Steven Lichtman – Oppenheimer & Company Josh Jennings – Cowen Operator Good morning, and welcome to the First Quarter 2022 Earnings Conference Call for Conformis. My name is Michelle, and I’ll be your conference operator today.
Zacks Investment Research
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
Wednesday May 04 2022 at 09:47
ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Conformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022
Monday Apr 11 2022 at 16:30
BILLERICA, Mass., April 11, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market opens on Wednesday, May 4, 2022, at approximately 7:00 a.m. Eastern Time.
Benzinga
Conformis’ Q4 Miss Street View As Earnings Impacted By Surge In COVID-19 Cases
Thursday Mar 03 2022 at 06:49
Conformis Inc’s (NASDAQ: CFMS) Q4 revenues decreased 8% Y/Y to $15.4 million, missing the consensus of $15.61 million. The decrease is primarily due to deferred and rescheduled elective surgeries due to increased COVID-19 cases associated with the Delta and Omicron variants.
Seeking Alpha
Conformis, Inc.’s (CFMS) CEO Mark Augusti on Q4 2021 Results – Earnings Call Transcript
Wednesday Mar 02 2022 at 18:45
Conformis, Inc.’s (CFMS) CEO Mark Augusti on Q4 2021 Results – Earnings Call Transcript
GlobeNewsWire
Conformis, Inc. to Participate in Upcoming Investor Conferences
Friday Feb 18 2022 at 16:30
BILLERICA, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in three upcoming investor conferences.
Zacks Investment Research
New Strong Sell Stocks for February 14th
Monday Feb 14 2022 at 11:40
CFMS, JD, and PZG have been added to the Zacks Rank #5 (Strong Sell) List on February 14, 2022
PennyStocks
Popular Penny Stocks to Know About as January Ends
Friday Jan 21 2022 at 17:00
Can these penny stocks make gains moving forward? The post Popular Penny Stocks to Know About as January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 2, 2022
Thursday Jan 20 2022 at 16:30
BILLERICA, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business Update call on January 6, 2022, it will release its financial results for the fourth quarter and fiscal year ended December 31, 2021, after the market closes on Wednesday, March 2, 2022, at approximately 4:00 p.m. Eastern Time.
Seeking Alpha
Conformis, Inc. (CFMS) CEO Mark Augusti on Q3 2021 Results – Earnings Call Transcript
Wednesday Nov 03 2021 at 20:10
Conformis, Inc. (CFMS) CEO Mark Augusti on Q3 2021 Results – Earnings Call Transcript
GlobeNewsWire
Conformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021
Monday Oct 04 2021 at 17:00
BILLERICA, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:00 p.m. Eastern Time.
Zacks Investment Research
Conformis (CFMS) Sees Hammer Chart Pattern: Time to Buy?
Monday Oct 04 2021 at 08:45
Conformis (CFMS) has been struggling lately, but the selling pressure may be coming to an end soon.
Benzinga
Conformis Posts Clinical Study Data For Its Knee Implants
Thursday Sep 30 2021 at 09:24
Conformis Inc (NASDAQ: CFMS) announced results of a published retrospective study of procedures using Conformis’ patient-specific iTotal CR (cruciate-retaining) knee replacement implant. Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.
GlobeNewsWire
Conformis, Inc. Announces Strong Clinical Study Results for Its Personalized Knee Implants
Wednesday Sep 29 2021 at 17:00
A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up
Conformis Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Conformis’s Altman Z-score is -12.53 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Conformis Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Conformis.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Conformis’s Income Quality of 1.07 is greater than its Industry Group of 0.68 (57.4% greater)
Conformis’s Income Quality of 1.07 is greater than its Major Industry Group of 0.71 (50.7% greater)
Conformis’s Income Quality of 1.07 is greater than its Sector of 0.75 (42.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Conformis’s Current Ratio of 5.07 is greater than its Industry Group of 3.36 (50.9% greater)
Conformis’s Current Ratio of 5.07 is greater than its Major Industry Group of 3.13 (62.0% greater)
Conformis’s Current Ratio of 5.07 is greater than its Sector of 2.6 (95.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.43 & -1.02)
Cannot compare a negative PE Ratio (-0.43 & -0.58)
Cannot compare a negative PE Ratio (-0.43 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Conformis’s PB Ratio of 0.56 is lower than its Industry Group of 1.9 (-70.5% lower)
Conformis’s PB Ratio of 0.56 is lower than its Major Industry Group of 1.93 (-71.0% lower)
Conformis’s PB Ratio of 0.56 is lower than its Sector of 1.62 (-65.4% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Conformis’s ROE of -1.3 is lower than its Industry Group of -0.26 (-400.0% lower)
Conformis’s ROE of -1.3 is lower than its Major Industry Group of -0.09 (-1344.4% lower)
Conformis’s ROE of -1.3 is lower than its Sector of -0.03 (-4233.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Conformis’s ROCE of -0.71 is lower than its Industry Group of -0.27 (-163.0% lower)
Conformis’s ROCE of -0.71 is lower than its Major Industry Group of -0.14 (-407.1% lower)
Conformis’s ROCE of -0.71 is lower than its Sector of -0.04 (-1675.0% lower)
Derived from SEC.GOV filing dataopen_in_new